Write in a clean editor, then format for Journal of Cardiovascular Pharmacology and Therapeutics in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Journal of Cardiovascular Pharmacology and Therapeutics is a peer-reviewed journal published by SAGE, covering Cardiac electrophysiology and arrhythmias, Cardiac Ischemia and Reperfusion, Atrial Fibrillation Management and Outcomes.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Journal of Cardiovascular Pharmacology and Therapeutics, 12(3), pp. 45–58.
Formats any DOI in Journal of Cardiovascular Pharmacology and Therapeutics style. No sign-up. |
| Publishes research in | Cardiac electrophysiology and arrhythmias Cardiac Ischemia and Reperfusion Atrial Fibrillation Management and Outcomes Lipoproteins and Cardiovascular Health Heart Failure Treatment and Management |
| ISSN | 1074-2484 |
| Citation impact (2-yr) | 1.75 |
| h-index | 68 |
| i10-index | 841 |
| Total citations | 29,658 |
| Article processing charge | $2,000 |
| Open access | Yes |
| Top institutions publishing here | University of Southern California |
| Journal website | www.sagepub.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The United States is experiencing its greatest life expectancy ever. Nonetheless, the general health of the US population is far from at an all-time high. An important contributor to the pandemic of cardiovascular disease is that overweight and obesity are also the major determinants of metabolic syndrome, an all too common and all too serious…
INTRODUCTION: Studies have shown that ticagrelor has a further adenosine-mediated mechanism of action in addition to its potent inhibition of the P2Y12 receptor, which may explain some of ticagrelor's clinical characteristics. This study aimed to further characterize the adenosine pharmacology of ticagrelor, its major metabolites, and other P2Y12 receptor antagonists. METHODS: Inhibition of nucleoside transporter-mediated…
Atherogenesis has been traditionally viewed as a metabolic disease representing arterial obstruction by fatty deposits in its wall. Today, it is believed that atherogenesis involves highly specific biochemical and molecular responses with constant interactions between various cellular players. Despite the presence of inflammatory reaction in each and every step of atherosclerosis from its inception to…
This paper summarizes the pharmacologic properties of vasoactive medications used in the treatment of shock, including the inotropes and vasopressors. The clinical application of these therapies is discussed and recent studies describing their use and associated outcomes are also reported. Comprehension of hemodynamic principles and adrenergic and non-adrenergic receptor mechanisms are salient to the appropriate…
AIMS: A routine secondary pharmacology screen indicated that reversibly binding oral P2Y(12) receptor antagonist ticagrelor could inhibit adenosine uptake in human erythrocytes, suggesting that ticagrelor may potentiate adenosine-mediated responses in vivo. The aim of this study was to further characterize the adenosine uptake inhibition in vitro and study possible physiological consequences of adenosine uptake inhibition…
Clinical Psychological Science
Comparative Political Studies
Current Directions in Psychological Science
Educational Researcher
Environment and Planning B: Urban Analytics and City Science
Exceptional Children
Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine
International Journal of Stroke
